⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.

Rasburicase

راسبوریکاز

⚠ Unverified

🧪 VariousRecombinant urate oxidase

🤰 Pregnancy:Dangerous / avoid 🤱 Breastfeeding:Dangerous / avoid 👶 Children:Use with caution 👴 Older adults:No specific problem stated 🇮🇷 Registered in Iran ⛔ 1 contraindications 🇺🇸 FDA approved (BLA) BLA103946 ATC V03AF07

Market / country: 🇺🇸 USA

Elitek (US)

🧮 Dose calculator

Disease / regimen

Tumour lysis syndrome hyperuricaemia · Regimen source: FDA Elitek · 2.1

• Not beyond 5 days or more than one course. Never bolus; dilute to 50 mL. Screen G6PD first. FDA Elitek · 2.1 FDA Elitek · 2.3 FDA Elitek · Boxed Warning

Formulation

Age *

Weight (kg) *

Enter age and weight.

🛡️ Safety & information

Contraindications

⛔ History of anaphylaxis or severe hypersensitivity, haemolysis or methaemoglobinaemia with rasburicase; G6PD deficiency. FDA Elitek · 4

Warnings

• Boxed warning: anaphylaxis, haemolysis (G6PD), methaemoglobinaemia and interference with uric acid measurement (sample on ice). FDA Elitek · Boxed Warning

Formulations

7.5 mg vial — powder for injection 🇺🇸 USA FDA Elitek · 3
1.5 mg vial — powder for injection 🇺🇸 USA FDA Elitek · 3

👥 Special populations

🤰 PregnancyDangerous / avoid
Label: can cause fetal harm. Dangerous in pregnancy. FDA Elitek · 8.1
“Risk Summary Based on findings in animals, Elitek may cause fetal harm when administered to pregnant women.”
🤱 BreastfeedingDangerous / avoid
Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Elitek · 8.2
“Because of the potential for serious adverse reactions in the breastfed child, advise patients that breastfeeding is not recommended during treatment with Elitek, and for 2 weeks after the last dose.”
👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Elitek · 8.4
“The safety and effectiveness of Elitek have been established in pediatric patients ages 1 month to 17 years for initial management of plasma uric acid levels in patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis and subsequent elevation …”
👴 Older adultsNo specific problem stated
Label: no specific difference or dose adjustment stated for older adults. FDA Elitek · 8.5
“No overall differences in pharmacokinetics, safety, and effectiveness were observed between the elderly and younger patients.”
⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.

🔗 Reference links

FDA (approval record)BLA103946
DailyMed (FDA label)FDA Elitek
MedlinePlus (NIH)Rasburicase Injection
WHO ATC/DDDV03AF07
Darooyab (Iran)Rasburicase

🇮🇷 Registered in Iran Darooyab · G-763/Rasburicase

Dosage forms with Iranian generic codes, per Darooyab.

12102 · RASBURICASE 1.5MG VIAL · ویال راسبوریکاس ۱٫۵ میلی‌گرم

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

FDA label (DailyMed)✅ Present
FDA Elitek · 3 FDA Elitek · 2.1 FDA Elitek · 2.3 FDA Elitek · Boxed Warning FDA Elitek · 4 FDA Elitek · SPL approval / marketing category FDA Elitek · 8.1 FDA Elitek · 8.2 FDA Elitek · 8.4 FDA Elitek · 8.5
UK SmPC (eMC / MHRA)❌ Not present
Published guideline❌ Not present
Licensed reference (medical school)❌ Not present
Iranian leaflet (IFDA)❌ Not present
Pharmacy website (secondary, unreliable)✅ Present
Darooyab · G-763/Rasburicase
Clinical review⚠ Unverified